Study of the Cephea Mitral Valve System to Treat Symptomatic Mitral Valve Disease Including Mitral Regurgitation and Mitral Stenosis Using Transcatheter Therapy Instead of Open Heart Surgery

What this Trial Is About

Researchers are evaluating the preliminary safety and effectiveness of the Cephea Mitral Valve System in treating symptomatic patients with mitral valve disease, including mitral regurgitation, mitral stenosis, and mixed mitral valve disease. The study focuses on patients for whom transcatheter therapy is considered more suitable than open heart surgery. This feasibility study is sponsored by Abbott Medical Devices and involves adult participants aged 18 years and older. Participants will receive treatment using the Cephea Mitral Valve System, a device designed to address mitral valve issues via a minimally invasive transcatheter approach. The study does not involve a control group or placebo and is not blinded. The primary outcomes measured 30 days after implant include freedom from all-cause mortality and reduction of mitral regurgitation to Grade I or less. During the study, participants will be monitored for safety and treatment effectiveness. Evaluations include assessments of mitral valve function and survival status at 30 days post-implant. Follow-up will help researchers understand the devices impact on mitral valve disease symptoms and patient outcomes. The total duration of participation may vary depending on individual follow-up schedules and assessments.

Cephea South America Feasibility Study